Effects of Interferon Alpha on Myeloma Cells: Mechanisms of Differential Responsiveness
Multiple myeloma is a progressive and fatal disease characterized by the accumulation of malignant plasma cells in the bone marrow. We have been interested in understanding the mechanisms of growth control in myeloma cells. By way of introduction, Figure 1 is a schematic depiction of the proposed progression from monoclonal gammopathy of undetermined significance (MGUS) into myeloma. The incidence of MGUS over the age of 60 has been shown to be approximately 1% and incidence increases to 3% in individuals over the age of 70 (reviewed in 1). Importantly, it has been shown that a significant proportion of MGUS patients will progress into myeloma over time (2). The key distinguishing features between MGUS and myeloma include the absence of lytic bone lesions (MGUS; 3) and differences in the proliferative index of the monoclonal plasma cell population. Thus, a well-documented change that occurs during the progression from MGUS to myeloma is an increase in the plasma cell labeling (proliferative index) of the plasma cell (LI; 4, 5). Because of the key differences between the growth properties displayed by benign (MGUS) and malignant (myeloma) plasma cells, we have had a keen interest in understanding the mechanisms of growth control. Figure 1 suggests that key changes that may occur during this progression include alterations in cytokine responsiveness, acquisition of autocrine growth factor expression, or alterations in cytokine receptor expression.
KeywordsMultiple Myeloma Myeloma Cell Myeloma Cell Line Plasma Cell Leukaemia Human Myeloma Cell Line
Unable to display preview. Download preview PDF.
- 8.Browman GP, Bergsagel D, Sicheri D, O’Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D (1995) Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 13:2354–2360PubMedGoogle Scholar
- 9.Ludwig H, Cohen AM, Polliack A, Huber H, Nachbaur D, Senn H-J, Morant R, Eckhardt S, Günczler P, Seewann HL, Schüller J, Rhyner K, Cavalli F, Fritz E (1995) Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Annals of Oncol 6:467–476Google Scholar
- 14.Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA (1993) Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: Clinical implications. Can Res 53:5320–5327Google Scholar
- 16.Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ (1997) Differential human multiple myeloma cell line responsiveness to interferon-α: Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest, in pressGoogle Scholar